The Food and Drug Administration requested additional data from Mannkind Corp. (Nasdaq: MNKD) for its inhalabel insulin Afrezza. Shares of the biopharmaceutical plunged $2.59 to close at $7.89.
FDA Requests Additional Data From Mannkind
March 15, 2010 at 17:06 PM EDT
